Clinical trials
Squamous Cell Non-small Cell Lung Cancer clinical trials
Below are recruiting squamous cell non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 393 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Mobile, AlabamaAges 18 years+ - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
Birmingham, AlabamaAges 18 years+ - NCT06596915RecruitingPhase 1
BA1302 for advanced solid tumors
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
BeijingAges 18 years+ - NCT06568939RecruitingPhase 2
Study of telisotuzumab vedotin for non-squamous lung cancer
This trial tests a drug called telisotuzumab vedotin (ABBV-399) given through a vein to people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a high level of a protein called c-Met. The study aims to see how the drug affects the body and helps control the cancer.
Chandler, ArizonaAges 18 years+ - NCT06561386RecruitingPhase 3
Testing a new drug combo for advanced lung cancer
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Mobile, AlabamaAges 18 years+ - NCT06567015RecruitingPhase 1/Phase 2
Study of a new drug for advanced lung cancer that stopped responding to current treatments
This trial tests a new medicine, STX-241, for people with a specific type of advanced lung cancer (NSCLC) that has stopped responding to current targeted therapies. The goal is to see if this new drug can help shrink or control the cancer.
Nashville, TennesseeAges 18 years+ - NCT06566443RecruitingPhase 1
Honokiol for early-stage lung cancer before surgery
This trial tests a natural compound called honokiol in people with early-stage non-small cell lung cancer who are scheduled for surgery. The goal is to see if honokiol can help shrink or control the tumor before it is removed.
Houston, TexasAges 18 years+ - NCT06545331RecruitingPhase 1
A study of XB010 for advanced solid tumors
This trial tests an investigational drug called XB010 for people with solid tumors that have spread or cannot be removed by surgery. It aims to see if XB010 is safe and effective for several cancer types, including lung, breast, head and neck, and esophageal cancers.
Irvine, CaliforniaAges 18 years+ - NCT06545747RecruitingPhase 3
MRI-guided radiation for advanced lung cancer
This trial tests a new way of giving radiation therapy for advanced lung cancer that cannot be surgically removed. It uses MRI scans to guide and adjust the radiation dose, which may help target the tumor more precisely and reduce side effects.
GuangzhouAges 18–75 - NCT06514027RecruitingPhase 2
Study of BEBT-109 for lung cancer with EGFR exon 20 insertion mutation
This trial tests a new drug called BEBT-109 for people with a specific type of non-small cell lung cancer that has an EGFR exon 20 insertion mutation. It's for those who haven't had prior treatment for advanced or metastatic lung cancer, and it aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06127303RecruitingPhase 2
Toripalimab plus cryoablation for lung cancer with limited progression
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06512051RecruitingPhase 1/Phase 2
Study of SHR-A2102 and Adebrelimab for advanced lung cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–70 - NCT06491862Recruiting
Real-world outcomes after first treatment for advanced lung cancer in Brazil
This study looks at real-world treatment patterns and outcomes for people with advanced non-squamous non-small cell lung cancer in Brazil after standard treatments have failed. It aims to understand what happens next and how well different approaches work in everyday practice.
Belo Horizonte, Minas GeraisAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Bullhead City, ArizonaAges 18 years+ - NCT06472245RecruitingPhase 3
Cancer vaccine for lung cancer that stopped responding to immunotherapy
This trial tests a therapeutic cancer vaccine called OSE2101 for people with advanced non-small cell lung cancer whose tumors stopped responding to an immunotherapy drug. The vaccine is designed to help your immune system fight the cancer in a different way.
Beverly Hills, CaliforniaAges 18 years+ - NCT06452277RecruitingPhase 3
Testing sevabertinib for advanced HER2-mutated lung cancer
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
Newport Beach, CaliforniaAges 18 years+ - NCT06444815RecruitingPhase 1
Study of VET3-TGI for advanced solid tumors
This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.
Los Angeles, CaliforniaAges 18 years+ - NCT06449313RecruitingPhase 2
Immunotherapy before lung cancer surgery for stage 3 disease
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help shrink stage 3 lung cancer and improve outcomes. The goal is to make the tumor easier to remove and possibly lower the chance of it coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06441773Recruiting
Lung rehab for advanced lung cancer on maintenance therapy
This study tests if a respiratory (breathing) rehabilitation program can improve quality of life for people with advanced non-small cell lung cancer who are on maintenance treatment after initial chemotherapy and immunotherapy.
BrestAges 18 years+ - NCT06437977RecruitingPhase 3
Pre-surgery treatment with radiation, immunotherapy, and chemo for stage II-III NSCLC
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
ShanghaiAges 18–75 - NCT06427941RecruitingPhase 1/Phase 2
Study of BGB-B2033 with other drugs for advanced solid tumors
This study tests a new drug called BGB-B2033, alone or with other drugs (tislelizumab and bevacizumab), in people with certain advanced cancers. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
Birmingham, AlabamaAges 18 years+ - NCT06416410RecruitingPhase 3
Combination targeted therapy for KRAS G12C lung cancer
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
Hefei, AnhuiAges 18 years+ - NCT06418204Recruiting
Cannabis use among cancer patients in community clinics
This study looks at how cancer patients use cannabis (marijuana) and cannabis products to manage symptoms during chemotherapy or immunotherapy. The goal is to learn about the benefits and risks so doctors can better guide patients.
Fairbanks, AlaskaAges 18 years+
Hear when a new Squamous Cell Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for squamous cell non-small cell lung cancer?
- Yes. Clin2 currently lists 393 recruiting squamous cell non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a squamous cell non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a squamous cell non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non-squamous Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- Non Small Cell Lung Cancer
- Squamous Non-small-cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Lung Non-Squamous Non-Small Cell Carcinoma
- NSCLC (Advanced Non-small Cell Lung Cancer)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.